Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension
EPICOR
EPICOR Asia-China Extension. Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension
2 other identifiers
observational
2,334
1 country
33
Brief Summary
This study is to describe the long-term antithrombotic management patterns in a real-life setting for patients hospitalized with an acute coronary syndrome in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2014
Typical duration for all trials
33 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 18, 2014
CompletedFirst Posted
Study publicly available on registry
December 3, 2014
CompletedStudy Start
First participant enrolled
December 17, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 5, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
April 5, 2017
CompletedSeptember 17, 2018
September 1, 2018
2.3 years
November 18, 2014
September 14, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Long-term antithrombotic management patterns in a real-life setting by assessing the medication and treatment prescribed by physicians
From 2 years after the acute coronary syndrome index event, assessed up to 5 years
Secondary Outcomes (3)
Clinical outcomes by record the number and type of cardiovascular and non-cardiovascular events
From 2 years after the acute coronary syndrome index event, assessed up to 5 years
Health care resource consumption and related costs by assessing the detail hospitalization and outpatient cost.
From 2 years after the acute coronary syndrome index event, assessed up to 5 years
Quality of life by assessing EQ-5D questionnaire.
2 years,2.5years,3years,3.5years,4years,4.5years,5years after the acute coronary syndrome index event
Eligibility Criteria
Patients with a history of acute coronary syndromes in China
You may qualify if:
- Written informed consent has been provided.
- Contact Order Form has been provided
- Aged 18 years or older.
- Enrolled in EPICOR Asia study and completed the 2 year follow-up.
You may not qualify if:
- Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances, alcohol or drug abuse).
- Already included in the EPICOR Asia-China Extension observational study.
- Presence of serious/severe co-morbidities in the opinion of the investigator which may limit short term (i.e. 6 month) life expectancy.
- Current participation in an interventional clinical trial.
- Patients receiving ticagrelor beyond 12 months and other off label use.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (33)
Research Site
Baoding, China
Research Site
Beijing, China
Research Site
Changzhi, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Guiyang, China
Research Site
Haerbin, China
Research Site
Hangzhou, China
Research Site
Hebei, China
Research Site
Jilin, China
Research Site
Jinan, China
Research Site
Jinzhong, China
Research Site
Kunming, China
Research Site
Lanzhou, China
Research Site
Nanjing, China
Research Site
Nanning, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shenzhen, China
Research Site
Shihezi, China
Research Site
Taiyuan, China
Research Site
Tangshan, China
Research Site
Tianjin, China
Research Site
Ürümqi, China
Research Site
Wuhan, China
Research Site
Wuxi, China
Research Site
Xi'an, China
Research Site
Xining, China
Research Site
Xuzhou, China
Research Site
Yinchuan, China
Research Site
Yulin, China
Research Site
Zhengzhou, China
Research Site
Zhenjiang, China
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yong Huo, Doctor
Peking University First Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 18, 2014
First Posted
December 3, 2014
Study Start
December 17, 2014
Primary Completion
April 5, 2017
Study Completion
April 5, 2017
Last Updated
September 17, 2018
Record last verified: 2018-09